Women with BRCA1 or BRCA2 mutations have a very high lifetime risk of developing breast and ovarian cancer. Women have options to reduce their risk of cancer. Options to reduce breast cancer risk ...

Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

Stanford scientists have identified 380 key genetic variants that significantly influence cancer development, filtering ...

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA).

Thousands of single changes in the nucleotides that make up the human genome have been associated with an increased risk of ...

BOISE — A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk patients ...

A new study on circulating tumor DNA (ctDNA) testing for advanced breast cancer has unveiled encouraging results, with high ...